"Valneva believes it is likely that the short interval between the second shot and booster shot could have adversely impacted the results for VLA2001, given that a longer interval is generally required for inactivated vaccines," Valneva said December 3 in a statement. Between June 1 and June 30, 2021, 3498 people were screened. 2878 participants met eligibility criteria and received COVID-19 vaccine or control. IDT Biologika Partners on Manufacturing –IDT Biologika has agreed to produce VLA2001's drug substance at its Biosafety Level 3 facilities in Dessau-Roßlau, Germany, in addition to Valneva's manufacturing site in Livingston, Scotland, IDT and Valneva said November 29. The value of the companies' agreement was not disclosed. EC Purchases Up to 60M Doses —Valneva said November 23 that it signed an advance purchase agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years.